Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for mild cognitive impairment or mild dementia due to Alzheimer’s disease in adults who are either ApoE4 non-carriers or heterozygous carriers. In response to February 2025 TGA decision not to approve lecanemab as a treatment for people with early AD, in March 2025, Eisai requested a review by the Administrative Review Tribunal. As a result of discussions during this process, the TGA and Eisai reached an agreement that led to the approval of LEQEMBI.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen complete response letter manageable, says Citi
- Biogen’s Growth Outlook: Navigating FDA Delays and Pipeline Maturation
- Biogen’s Hold Rating Maintained Amid Uncertainty Over FDA’s CRL on Nusinersen
- Biogen’s Spinraza High-Dose Application Faces Technical Hurdle, Buy Rating Maintained
- FDA requests update to technical information of Biogen nusinersen sNDA